Meridian Bioscience Inc (VIVO) 20.47 $VIVO
Global Isothermal Nucleic Acid Amplification Technologies Market 2014: Becton, Dickson and Co., bioMerieux S.A., Hologic Inc., Novartis International AG., and Quidel Dominate
M2 - Wed May 07, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9msx5l/global_isothermal) has announced the addition of the "Global Isothermal Nucleic Acid Amplification Technologies Market 2014: Becton, Dickson and Co., bioMerieux S.A., Hologic Inc., Novartis International AG., and Quidel Dominate" report to their offering. The Global Isothermal Nucleic Acid Amplification Technologies market will grow at a CAGR of 17% to 2018. One of the major drivers in this market is the technological advancements. Isothermal amplification-based technologies and their variants are being developed to address the diagnosis of many infectious disease- causing pathogens. Based on the mechanisms of the strand displacement properties of DNA polymerases, helicases, and other catalytic factors, many isothermal amplification methods have been developed. The Molecular Diagnostics industry is experiencing a rapid shift toward an increase in the process automation and integration of sample analysis in single miniaturized devices. Miniaturization offers scope for reduced sample volume, enabling the end-user to automate and analyze the sample. Among all the diagnostic methods, nucleic acid testing remains the method with the most potential for conducting analysis in miniaturized devices. Although PCR is one of the standard techniques for conducting amplification reaction, the method is quite complex due to the need for repeated thermo cycling and cooling, and it consumes more energy in the process. As an alternative to PCR, isothermal nucleic amplification circumvents the need for repeated denaturation and cooling as the amplification reaction occurs under isothermal conditions. This greatly aids in the design of microfluidic chips for conducting molecular diagnostics. Most of these microfluidic devices adopting isothermal nucleic acid amplification methods are in the R&D phase. It is expected that the increase in miniaturization of nucleic acid-based diagnostics will boost the growth of the market. Further, the report states that one of the major challenges in this market is the intense competition from PCR-based diagnostics. PCR-based diagnostics still remains the gold standard method for the amplification of nucleic acids owing to the popularity and wide range of product manufacturers. The key vendors dominating this space are: - Becton, Dickson and Co. - bioMerieux S.A. - Hologic Inc. - Novartis International AG. - Quidel Corp. The other vendors mentioned in the report are: - Alere Inc. - Axxin Pvt Ltd. - Eiken Chemical Co. Ltd. - Great Basin Corp. - Lucigen Corp. - Meridian Bioscience Inc. - New England Biolabs Inc. - Optigene Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Market Segmentation by Technology - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/9m...isothermal
Global Hospital Acquired Disease Testing Market 2013-2019: Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others
M2 - Tue Apr 29, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3dns5j/hospital_acquired) has announced the addition of the "Global Hospital Acquired Disease Testing Market 2013-2019: Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others" report to their offering. This report covers the market analysis for various diagnostic tests performed to detect hospital associated infections, also called as nosocomial infections. Morbidity rate of nosocomial infections is increasing rapidly worldwide,thereby driving the hospital associated infection (HAI) diagnostic market towards remarkable growth. The stakeholders for this study include manufacturers and providers of diagnostic solutions for nosocomial infections. The global hospital acquired disease testing market is categorized on the basis of infection types,i.e., urinary tract infection, surgical site infection, pneumonia,blood stream infection, MRSA infection and others. A detailed market analysis and forecast for these segments has been provided in this study, in terms of market revenue (USD million) for the period 2011 to 2019.The report also provides the compounded annual growth rate (CAGR %) for each infection type for the forecast period 2013 to 2019, while market size estimations have been made considering 2012 as the base year. In terms of geographical distribution, the global hospital acquired disease testing market has been classified into four geographical areas, namely North America, Europe, Asia-Pacific and Rest of the World (RoW). The current and future market sizes (in terms of USD million) of the above regional markets have been provided in the report for the period 2011 to 2019 with their growth rate (%) for the period 2013 to 2019. The study further offers recommendations and highlights of the market, which would be useful for the current and future market players to sustain and grow in the global hospital acquired disease testing market. The market overview section of the report demonstrates the market dynamics and market trends such as the drivers, restraints and opportunities that influence the current nature and future status of this field. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global hospital acquired disease testing market. This report concludes with the company profiles section which includes key information about the major players in this market. Some of the key players profiled in this report include Diatherix Laboratories Inc., Gen-Probe Inc., Qiagen GmbH, L Hoffman La Roche,Cepheid, Inc., Life Technologies Corporation, Meridian Biosciences, Cantel Medical Corporation, Nordion, Inc.and others. Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Hospital Acquired Disease Testing, by Infection Type - Global Hospital Acquired Disease Testing, by Geography - Recommendations - Company Profiles - Abbott Laboratories, Inc. - Alere, Inc. - bioMerieux, Inc. - Becton, Dickinson and Company - Cantel Medical Corporation - Cepheid, Inc. - Diatherix Laboratories Inc. - F. Hoffman-La Roche, Ltd. - Gen-Probe, Inc. - Life Technologies Corporation - Meridian Bioscience, Inc. - Nordion, Inc. - Qiagen GmbH For more information visit http://www.researchandmarkets.com/research/3d...l_acquired
Global Enteric Disease Testing Market 2014-2018: Alere, bioMerieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market
M2 - Mon Apr 28, 11:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s27mxj/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018: Alere, bioM?rieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market" report to their offering. One of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. The discovery and characterization of new emerging viruses and bacteria is playing an important role in the Diagnostics industry. Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. Further, the report states that one of the major challenges in the market is the presence of stringent regulatory approval processes for clinical in-vitro diagnostic tests for enteric disease identification. Key vendors dominating this space are: - Alere Inc - bioM?rieux SA - Bio-Rad Laboratories Inc. - Cepheid Inc. - DiaSorin S.p.A. Other vendors mentioned in the report are: - Affymetrix Inc. - Beckton, Dickenson and Co - Biomerica Inc - Coris BioConcept - Danaher Corp. - Meridian Bioscience Inc. - Quest Diagnostics Inc. - R-Biopharm AG - Trinity Biotech PLC. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Type of Diseases - Types of Clinical Diagnostic Testing - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s2...al_enteric
Meridian Bioscience Reports Second Quarter 2014 Operating Results and Revises Fiscal 2014 Guidance
Business Wire - Thu Apr 24, 6:31AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO):
Meridian Bioscience Slips to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 1:50PM CDT
Meridian's adjusted earnings per share decreased 10% year over year to 18 cents during first-quarter fiscal 2014.
Balanced View on Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:20PM CDT
On Apr 4, we issued an updated research report on Genomic Health.
Edwards' Intuity Elite Cleared in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:10PM CDT
Edwards Lifesciences has received CE Mark approval for its Intuity Elite valve system.
New Jobs at Baxter's Malta Facility - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:03PM CDT
BAX is seen making efforts to meet its current and future business needs by investing in its manufacturing infrastructure and employee capabilities.
Boston Scientific Posts Encouraging CRT-TAVR Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 2:00PM CDT
Boston Scientific's shares gained 0.8% in the trading session that followed the release of the study results.
Covidien's Ablation System: A Sure Winner - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:25PM CDT
Covidien recently announced results from its SURF clinical trial, reporting that its Barrx RF Ablation System proved effective in treating patients with Barrett's esophagus.
Positive MADIT-CRT Data at Boston Scientific - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:16PM CDT
BSX presented encouraging long-term results from the Multicenter Automatic Defibrillator Implantation ??? Cardiac Resynchronization Therapy (MADIT-CRT) clinical trial at the American College of Cardiology.
FDA Clears Meridian's B. Pertussis Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:40PM CDT
Meridien's Illumigene Pertussis is superior to conventional Bordetella pertussis bacterial culture.
Covidien Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:10PM CDT
Covidien posted strong fiscal first-quarter results recording year-over-year increases both in revenues and adjusted earnings.
The Market and Potential for Molecular Point of Care Diagnostics Report Provides Market Estimates up to 2018
M2 - Mon Mar 31, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb6tbz/the_market_and) has announced the addition of the "The Market and Potential for Molecular Point of Care Diagnostics" report to their offering. The molecular diagnostic market and the point-of-care (POC) testing markets are two of the fastest growing segments of the overall IVD market. Historically, these have been completely different market segments. Not anymore. There has been a growing interest in developing molecular diagnostic platforms that can be used in POC settings. Indeed, as this new market research report details, the emerging area of rapid molecular POC testing has attracted over $650 million in investments and financings over the past five years (2009 to 2013). The Market and Potential for Molecular Point of Care Diagnostics, offers a quantitative assessment of the molecular diagnostic market, and of the point-of-care (POC) testing market, and then looks at the emerging field of molecular diagnostic POC testing. Many companies are developing molecular diagnostic platforms and assays that are designed to for near-patient or POC testing, and the earliest of these systems are starting to reach the market. The initial market focus for most of these companies is on infectious disease testing, where rapid test results generate important actionable information that physicians can use to make treatment decisions. Over 75 companies involved in this market are profiled in this report. As expected with any group of start-up companies, many are struggling or are surviving on limited financial resources. However, some new companies that are focusing on molecular diagnostic POC testing have received significant investments. Some of the Companies Mentioned: - Abacus Diagnostica Oy - bioMerieux sa - Canon U.S. Life Sciences - DiaSorin S.p.A. - Espira, Inc. - Focus Diagnostics, Inc. - GenePOC Inc. - Instrumentation Laboratory - Lumora Ltd - Meridian Bioscience, Inc. - NetBio, Inc. - OptiGene Ltd. - PositiveID Corporation - QIAGEN N.V - Spartan Bioscience Inc. - Veredus Laboratories - Wave 80 Biosciences - Xagenic Inc. For more information visit http://www.researchandmarkets.com/research/gb...market_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Perrigo Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:30PM CDT
Perrigo inked a deal to manufacture store brand versions of nutritional drinks for adults.
Balanced View on Hanger - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:50PM CDT
We are impressed with the Hanger's higher revenues and EPS guidance riding on improvements in Patient Care segment.
Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene(R) Pertussis
Business Wire - Thu Mar 27, 1:05PM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Bordetella pertussis (B. pertussis), its fifth assay on the illumigene platform. This innovative test is the first FDA-cleared molecular stand-alone assay for B. pertussis providing a solution to the unmet need of today's healthcare market.
Baxter Downgraded to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 11:10AM CDT
Baxter's operating margin dropped 280 basis points (bps) year over year to 21% in the quarter.
Neogen Meets Q3 Earnings Ests, Beats Rev - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 9:50AM CDT
Neogen reported flat year over year adjusted earnings per share of 18 cents for the third quarter of fiscal 2014, in line with the Zacks Consensus Estimate.
St. Jude Medical's Prodigy Neurostimulator Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 3:00PM CDT
St. Jude Medical's Prodigy Chronic Pain System is based on neurostimulation therapy in addition to Burst Technology.
Global Isothermal Nucleic Acid Amplification Technologies Market 2014: Becton, Dickson and Co., bioMerieux S.A., Hologic Inc., Novartis International AG., and Quidel Dominate
M2 - Wed May 07, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9msx5l/global_isothermal) has announced the addition of the "Global Isothermal Nucleic Acid Amplification Technologies Market 2014: Becton, Dickson and Co., bioMerieux S.A., Hologic Inc., Novartis International AG., and Quidel Dominate" report to their offering. The Global Isothermal Nucleic Acid Amplification Technologies market will grow at a CAGR of 17% to 2018. One of the major drivers in this market is the technological advancements. Isothermal amplification-based technologies and their variants are being developed to address the diagnosis of many infectious disease- causing pathogens. Based on the mechanisms of the strand displacement properties of DNA polymerases, helicases, and other catalytic factors, many isothermal amplification methods have been developed. The Molecular Diagnostics industry is experiencing a rapid shift toward an increase in the process automation and integration of sample analysis in single miniaturized devices. Miniaturization offers scope for reduced sample volume, enabling the end-user to automate and analyze the sample. Among all the diagnostic methods, nucleic acid testing remains the method with the most potential for conducting analysis in miniaturized devices. Although PCR is one of the standard techniques for conducting amplification reaction, the method is quite complex due to the need for repeated thermo cycling and cooling, and it consumes more energy in the process. As an alternative to PCR, isothermal nucleic amplification circumvents the need for repeated denaturation and cooling as the amplification reaction occurs under isothermal conditions. This greatly aids in the design of microfluidic chips for conducting molecular diagnostics. Most of these microfluidic devices adopting isothermal nucleic acid amplification methods are in the R&D phase. It is expected that the increase in miniaturization of nucleic acid-based diagnostics will boost the growth of the market. Further, the report states that one of the major challenges in this market is the intense competition from PCR-based diagnostics. PCR-based diagnostics still remains the gold standard method for the amplification of nucleic acids owing to the popularity and wide range of product manufacturers. The key vendors dominating this space are: - Becton, Dickson and Co. - bioMerieux S.A. - Hologic Inc. - Novartis International AG. - Quidel Corp. The other vendors mentioned in the report are: - Alere Inc. - Axxin Pvt Ltd. - Eiken Chemical Co. Ltd. - Great Basin Corp. - Lucigen Corp. - Meridian Bioscience Inc. - New England Biolabs Inc. - Optigene Ltd. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Market Segmentation by Technology - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/9m...isothermal
Global Hospital Acquired Disease Testing Market 2013-2019: Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others
M2 - Tue Apr 29, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3dns5j/hospital_acquired) has announced the addition of the "Global Hospital Acquired Disease Testing Market 2013-2019: Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others" report to their offering. This report covers the market analysis for various diagnostic tests performed to detect hospital associated infections, also called as nosocomial infections. Morbidity rate of nosocomial infections is increasing rapidly worldwide,thereby driving the hospital associated infection (HAI) diagnostic market towards remarkable growth. The stakeholders for this study include manufacturers and providers of diagnostic solutions for nosocomial infections. The global hospital acquired disease testing market is categorized on the basis of infection types,i.e., urinary tract infection, surgical site infection, pneumonia,blood stream infection, MRSA infection and others. A detailed market analysis and forecast for these segments has been provided in this study, in terms of market revenue (USD million) for the period 2011 to 2019.The report also provides the compounded annual growth rate (CAGR %) for each infection type for the forecast period 2013 to 2019, while market size estimations have been made considering 2012 as the base year. In terms of geographical distribution, the global hospital acquired disease testing market has been classified into four geographical areas, namely North America, Europe, Asia-Pacific and Rest of the World (RoW). The current and future market sizes (in terms of USD million) of the above regional markets have been provided in the report for the period 2011 to 2019 with their growth rate (%) for the period 2013 to 2019. The study further offers recommendations and highlights of the market, which would be useful for the current and future market players to sustain and grow in the global hospital acquired disease testing market. The market overview section of the report demonstrates the market dynamics and market trends such as the drivers, restraints and opportunities that influence the current nature and future status of this field. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global hospital acquired disease testing market. This report concludes with the company profiles section which includes key information about the major players in this market. Some of the key players profiled in this report include Diatherix Laboratories Inc., Gen-Probe Inc., Qiagen GmbH, L Hoffman La Roche,Cepheid, Inc., Life Technologies Corporation, Meridian Biosciences, Cantel Medical Corporation, Nordion, Inc.and others. Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Hospital Acquired Disease Testing, by Infection Type - Global Hospital Acquired Disease Testing, by Geography - Recommendations - Company Profiles - Abbott Laboratories, Inc. - Alere, Inc. - bioMerieux, Inc. - Becton, Dickinson and Company - Cantel Medical Corporation - Cepheid, Inc. - Diatherix Laboratories Inc. - F. Hoffman-La Roche, Ltd. - Gen-Probe, Inc. - Life Technologies Corporation - Meridian Bioscience, Inc. - Nordion, Inc. - Qiagen GmbH For more information visit http://www.researchandmarkets.com/research/3d...l_acquired
Global Enteric Disease Testing Market 2014-2018: Alere, bioMerieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market
M2 - Mon Apr 28, 11:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s27mxj/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018: Alere, bioM?rieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market" report to their offering. One of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. The discovery and characterization of new emerging viruses and bacteria is playing an important role in the Diagnostics industry. Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. Further, the report states that one of the major challenges in the market is the presence of stringent regulatory approval processes for clinical in-vitro diagnostic tests for enteric disease identification. Key vendors dominating this space are: - Alere Inc - bioM?rieux SA - Bio-Rad Laboratories Inc. - Cepheid Inc. - DiaSorin S.p.A. Other vendors mentioned in the report are: - Affymetrix Inc. - Beckton, Dickenson and Co - Biomerica Inc - Coris BioConcept - Danaher Corp. - Meridian Bioscience Inc. - Quest Diagnostics Inc. - R-Biopharm AG - Trinity Biotech PLC. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Type of Diseases - Types of Clinical Diagnostic Testing - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s2...al_enteric
Meridian Bioscience Reports Second Quarter 2014 Operating Results and Revises Fiscal 2014 Guidance
Business Wire - Thu Apr 24, 6:31AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO):
Meridian Bioscience Slips to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 1:50PM CDT
Meridian's adjusted earnings per share decreased 10% year over year to 18 cents during first-quarter fiscal 2014.
Balanced View on Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:20PM CDT
On Apr 4, we issued an updated research report on Genomic Health.
Edwards' Intuity Elite Cleared in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 2:10PM CDT
Edwards Lifesciences has received CE Mark approval for its Intuity Elite valve system.
New Jobs at Baxter's Malta Facility - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 5:03PM CDT
BAX is seen making efforts to meet its current and future business needs by investing in its manufacturing infrastructure and employee capabilities.
Boston Scientific Posts Encouraging CRT-TAVR Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 2:00PM CDT
Boston Scientific's shares gained 0.8% in the trading session that followed the release of the study results.
Covidien's Ablation System: A Sure Winner - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 5:25PM CDT
Covidien recently announced results from its SURF clinical trial, reporting that its Barrx RF Ablation System proved effective in treating patients with Barrett's esophagus.
Positive MADIT-CRT Data at Boston Scientific - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 4:16PM CDT
BSX presented encouraging long-term results from the Multicenter Automatic Defibrillator Implantation ??? Cardiac Resynchronization Therapy (MADIT-CRT) clinical trial at the American College of Cardiology.
FDA Clears Meridian's B. Pertussis Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 3:40PM CDT
Meridien's Illumigene Pertussis is superior to conventional Bordetella pertussis bacterial culture.
Covidien Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 4:10PM CDT
Covidien posted strong fiscal first-quarter results recording year-over-year increases both in revenues and adjusted earnings.
The Market and Potential for Molecular Point of Care Diagnostics Report Provides Market Estimates up to 2018
M2 - Mon Mar 31, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gb6tbz/the_market_and) has announced the addition of the "The Market and Potential for Molecular Point of Care Diagnostics" report to their offering. The molecular diagnostic market and the point-of-care (POC) testing markets are two of the fastest growing segments of the overall IVD market. Historically, these have been completely different market segments. Not anymore. There has been a growing interest in developing molecular diagnostic platforms that can be used in POC settings. Indeed, as this new market research report details, the emerging area of rapid molecular POC testing has attracted over $650 million in investments and financings over the past five years (2009 to 2013). The Market and Potential for Molecular Point of Care Diagnostics, offers a quantitative assessment of the molecular diagnostic market, and of the point-of-care (POC) testing market, and then looks at the emerging field of molecular diagnostic POC testing. Many companies are developing molecular diagnostic platforms and assays that are designed to for near-patient or POC testing, and the earliest of these systems are starting to reach the market. The initial market focus for most of these companies is on infectious disease testing, where rapid test results generate important actionable information that physicians can use to make treatment decisions. Over 75 companies involved in this market are profiled in this report. As expected with any group of start-up companies, many are struggling or are surviving on limited financial resources. However, some new companies that are focusing on molecular diagnostic POC testing have received significant investments. Some of the Companies Mentioned: - Abacus Diagnostica Oy - bioMerieux sa - Canon U.S. Life Sciences - DiaSorin S.p.A. - Espira, Inc. - Focus Diagnostics, Inc. - GenePOC Inc. - Instrumentation Laboratory - Lumora Ltd - Meridian Bioscience, Inc. - NetBio, Inc. - OptiGene Ltd. - PositiveID Corporation - QIAGEN N.V - Spartan Bioscience Inc. - Veredus Laboratories - Wave 80 Biosciences - Xagenic Inc. For more information visit http://www.researchandmarkets.com/research/gb...market_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Perrigo Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:30PM CDT
Perrigo inked a deal to manufacture store brand versions of nutritional drinks for adults.
Balanced View on Hanger - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 2:50PM CDT
We are impressed with the Hanger's higher revenues and EPS guidance riding on improvements in Patient Care segment.
Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene(R) Pertussis
Business Wire - Thu Mar 27, 1:05PM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Bordetella pertussis (B. pertussis), its fifth assay on the illumigene platform. This innovative test is the first FDA-cleared molecular stand-alone assay for B. pertussis providing a solution to the unmet need of today's healthcare market.
Baxter Downgraded to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 11:10AM CDT
Baxter's operating margin dropped 280 basis points (bps) year over year to 21% in the quarter.
Neogen Meets Q3 Earnings Ests, Beats Rev - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 9:50AM CDT
Neogen reported flat year over year adjusted earnings per share of 18 cents for the third quarter of fiscal 2014, in line with the Zacks Consensus Estimate.
St. Jude Medical's Prodigy Neurostimulator Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 3:00PM CDT
St. Jude Medical's Prodigy Chronic Pain System is based on neurostimulation therapy in addition to Burst Technology.
